Velzatinib for Gastrointestinal Stromal Tumors

This trial tests a new treatment called velzatinib for individuals with gastrointestinal stromal tumors (GIST) that have spread or cannot be surgically removed. It compares velzatinib to imatinib, the current standard treatment, to determine if velzatinib can more effectively delay disease progression and ensure safety. The trial seeks participants with a confirmed diagnosis of metastatic GIST or GIST that cannot be surgically removed, who have not received prior treatment for the condition. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking treatment advancements.

Previous studies have shown velzatinib to be safe for treating advanced gastrointestinal stromal tumors (GIST). Patients generally tolerate it well, experiencing no severe side effects across different genetic types of GIST.

The treatment under comparison, imatinib, is already widely used for GIST and is known for its safety. Research indicates that imatinib is usually well tolerated, with most side effects being mild, such as nausea or vomiting, and serious side effects are rare.

Researchers are excited about Velzatinib for gastrointestinal stromal tumors (GIST) because it targets the cancer cells in a unique way, potentially offering an alternative to standard treatments like Imatinib, Sunitinib, and Regorafenib. Unlike these current options, which primarily focus on inhibiting certain enzymes driving tumor growth, Velzatinib may work on a different pathway, making it a promising candidate for patients who have become resistant to existing drugs. This new mechanism of action could provide hope for improved effectiveness and outcomes in treating GIST. Imatinib, another treatment in the trial, is already a well-known and widely used option, but researchers are exploring different combinations to enhance its efficacy.

Research has shown that velzatinib holds promise for treating gastrointestinal stromal tumors (GIST). In earlier studies, velzatinib reduced tumors in all patients who used it as their first treatment, with an average of 13.7 months before disease progression. As a second treatment option, about 35% of patients experienced tumor shrinkage. In this trial, participants will receive either velzatinib or the current standard treatment, imatinib. Imatinib is effective, with an average of 18 months before disease progression. However, tumors can become resistant to imatinib over time, highlighting the importance of new treatments like velzatinib for future care options.³⁶⁷⁸⁹